|
Jul 4
|
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
|
|
Jul 3
|
Switzerland seeks trade deal with Trump without getting into EU bind
|
|
Jul 3
|
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
|
|
Jul 2
|
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
|
|
Jun 30
|
Changes to the Roche Enlarged Corporate Executive Committee
|
|
Jun 26
|
Innovation in Focus: Highlights from the Two-Day London Biotechnology Show 2025
|
|
Jun 25
|
96% of health care executives are "ready and resourced" to use digital health solutions, yet two-thirds say interoperability is "a tough but manageable challenge," reveals new MIT Technology Review Insights report
|
|
Jun 23
|
Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug
|
|
Jun 23
|
Roche and Genentech’s Lunsumio-Polivy shows promise in Phase III trial
|
|
Jun 23
|
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
|
|
Jun 20
|
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
|
|
Jun 20
|
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
|
|
Jun 19
|
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
|
|
Jun 17
|
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
|
|
Jun 17
|
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
|
|
Jun 16
|
Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy
|
|
Jun 16
|
Genentech Provides Update on Phase III Verona Study
|
|
Jun 16
|
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
|
|
Jun 16
|
Sarepta and Roche halt DMD gene therapy’s use after second death
|
|
Jun 16
|
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
|